stockrowRoivant Sciences Ltd.
ROIV Healthcare Biotechnology
Roivant Sciences Ltd.’s revenue for fiscal 2026 (year ended March 2026) was $8.3 million, down 71.6% from fiscal 2025.
- Revenue
- −33.6%
- EPS
- +21.2%
- Free cash flow
- −30.0%
Quarter to June 2026, against a year earlier
Follow ROIV
Alert me
Roivant Sciences Ltd. (ROIV) P/B ratio
As of 5 November 2026, Roivant Sciences Ltd. (ROIV) trades at a P/B ratio of 5.4×. Over the past ten years it has ranged from 0.0× (December 2020) to 16.8× (February 2021); the current reading is higher than 88% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2026 | 3.7× | 160.45% |
| FY2025 | 1.4× | 11.38% |
| FY2024 | 1.3× | (61.29%) |
| FY2023 | 3.3× | 101.65% |
| FY2022 | 1.6× | (46.29%) |
| FY2021 | 3.0× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2026 | 5.2× | 41.03% |
| Mar 2026 | 3.7× | 20.88% |
| Dec 2025 | 3.0× | 41.79% |
| Sep 2025 | 2.1× | 34.67% |
| 21 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| BNTX BioNTech SE Sponsored ADR compare | 1.1× |
| RPRX Royalty Pharma PLC compare | 3.1× |
| INCY Incyte Corporation compare | 4.3× |
| ROIV Roivant Sciences Ltd. | 5.4× |
| GMAB Genmab A/S Sponsored ADR compare | 5.5× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 5.8× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 7.5× |
| RVMD Revolution Medicines, Inc. compare | 16.1× |
| INSM Insmed, Inc. compare | 32.6× |
| Biotechnology industry median | 2.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on ROIV
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement